# Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Study · id `cardio:ct-nct06399835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06399835](<https://clinicaltrials.gov/study/NCT06399835>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06399835

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06399835. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06399835, source copy `cardio:ctgov-nct06399835-2026-05-05`, retrieved 2026-10-26)
- Started: 2024-02-01 (actual) (ClinicalTrials.gov record NCT06399835, source copy `cardio:ctgov-nct06399835-2026-05-05`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06399835, source copy `cardio:ctgov-nct06399835-2026-05-05`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06399835, source copy `cardio:ctgov-nct06399835-2026-05-05`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06399835, source copy `cardio:ctgov-nct06399835-2026-05-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06399835-2026-05-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
- Condition: Type 2 Diabetes
- Intervention (Drug): Enavogliflozin
- Intervention (Drug): Pioglitazone
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER
- Collaborator: Daewoong Pharmaceutical Co. LTD.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)
- Registry lists this organization as a collaborator: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 721370cafd06d4a426901ba0ee530c888118bbbc409d8c4a76bdff3764c2b1e1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
